MedTrace Logo

Treatment of Intrabony Defects With Simvastatin and Antimicrobial Photodynamic Therapy

NCT05031923 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-04-11

No results posted yet for this study

Summary

Antimicrobial photodynamic therapy (aPDT) is characterized by the association of photosensitizing agents, promoting the generation of reactive oxygen species like free radicals and singlet oxygen, which are cytotoxic to certain bacteria. Simvastatin (SMV) enhances alkaline phosphatase activity and increases the expression of bone sialoprotein, osteocalcin, and type I collagen and is shown to have an anti-inflammatory effect by decreasing the production of C-reactive protein (CRP), IL-6, and IL-8. SMV is also reported to stimulate VEGF release in a dose-dependent manner which promotes osteoblast differentiation and bone nodule formation. The aim of this study is to evaluate the adjunctive effects of SMV with and without aPDT in chronic periodontitis patients.

Conditions

  • Simvastatin
  • Photodynamic Therapy
  • Periodontal Diseases

Interventions

PROCEDURE

SMV and antimicrobial photodynamic therapy

Application of SMV and antimicrobial photodynamic therapy in intrabony defects

PROCEDURE

SMV application

Application of SMV without antimicrobial photodynamic therapy in intrabony defects

Sponsors & Collaborators

  • Kafrelsheikh University

    lead OTHER

Principal Investigators

  • Dalia R Issa, PhD · Kafrelsheikh University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-16
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031923 on ClinicalTrials.gov